WO2006049078A1 - 皮膚疾患治療用外用剤 - Google Patents
皮膚疾患治療用外用剤 Download PDFInfo
- Publication number
- WO2006049078A1 WO2006049078A1 PCT/JP2005/019784 JP2005019784W WO2006049078A1 WO 2006049078 A1 WO2006049078 A1 WO 2006049078A1 JP 2005019784 W JP2005019784 W JP 2005019784W WO 2006049078 A1 WO2006049078 A1 WO 2006049078A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- skin
- drug
- water
- external preparation
- affected area
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
Definitions
- the present invention relates to an external preparation for treating skin diseases such as psoriasis.
- sealing closure therapy has a problem of increasing the side effects of the drug.
- the stratum corneum of the skin has a water content of about 10% under normal conditions. Keratin, which is the main component of the skin, has the property of absorbing water. If it is%, the amount of stratum corneum will increase by 10-30%.
- the drug in the applied formulation Since the agent diffuses into the stratum corneum according to the concentration difference, transdermal absorbability increases due to an increase in the amount of stratum corneum. In addition, since the drug can easily move in the stratum corneum, the amount transferred to the dermis also increases. As a result, side effects such as skin atrophy and dilation of capillaries became serious, especially when steroids were used in sealing closure therapy.
- Sealing closure therapy is not a force if it cannot be used for moist lesions such as ulcers, and side effects are particularly problematic in infants who are prone to systemic effects and elderly people who have a high amount of drug absorption of skin force. It becomes.
- the sealing closure therapy may cause bacterial infections such as keratitis and sweating caused by sweat accumulation. Also, especially in the summer, the affected area may get muddy and even stink.
- Japanese Patent Application Laid-Open No. 11-130679 discloses a nail psoriasis treatment cure solution containing a glucocorticoid (a kind of steroid), a solvent and a water-insoluble film forming agent.
- the preparation is a cure liquid for nail psoriasis, and is intended for quick drying. Therefore, the solvent used in each example includes 96% ethanol! /, But also includes lipophilic ethyl acetate and butyl acetate.
- the said cure liquid is an organic solvent solution of an organic polymer, the film formed after drying becomes very dense and does not have the ability to dissipate water. As a result, when it is applied to affected skin diseases, problems similar to those of sealed closure therapy such as side effects and stuffiness of steroids occur.
- Japanese Patent Application Laid-Open No. 13-521914 describes a method of forming a film by applying a cyanoacrylate ester composition to an affected area of skin disease and polymerizing it in situ.
- the composition is similar to a so-called instant adhesive and does not dissipate water, problems similar to those of the sealed closure therapy still occur.
- the [Technical field to which the invention belongs] section of the document clearly states that the coating formed by the composition functions as a blocking layer.
- JP-A No. 13-513549 discloses a cation polymer and a cationic polymer. Substances containing are described which form a film or gel in the presence of water.
- film or gel since each polymer is mutually bridge
- gelling Even though it is film-like, it is a gel in the academic definition. In such a case, water molecules bonded to the periphery of the polar group cannot evaporate, and moisture is always included. As a result, water is given to the affected area, and naturally the water in the affected area is not dissipated. Therefore, if the preparation is applied to the affected area of the skin disease, the same problem as that of the sealed closure therapy occurs.
- the problem to be solved by the present invention is an external preparation capable of covering the affected area in order to make the affected area less noticeable or to positively remove debris and the like caused by excessive proliferation of skin cells. Therefore, it is intended to provide a product in which side effects due to stuffiness and excessive absorption of drugs are suppressed.
- the inventors of the present invention have made extensive studies on components for forming a film in the affected area, particularly for solving the above problems. As a result, if the affected area is covered with a suspension of a so-called emulsion type adhesive component in water, moisture in the affected area can be dissipated as the water evaporates, and the humidity of the affected area can be kept moderate even after drying. Thus, the present invention was completed by discovering that it is possible to suppress the stuffiness of the affected area and excessive absorption of the drug.
- the external preparation for treating skin diseases of the present invention is characterized by comprising an emulsion type adhesive component, water, and a medicament for treating skin diseases.
- FIG. 1 Shows the results of a moisture permeation test on samples.
- the Y axis represents the water loss from the beginning as the amount of water permeation of each sample, and the X axis represents the elapsed time.
- Skin diseases targeted by the external preparation for treatment of skin diseases of the present invention are not particularly limited as long as they are other than those that may be adversely affected by the immunity-suppressing action of drugs such as infectious diseases or the covering of affected areas.
- drugs such as infectious diseases or the covering of affected areas.
- psoriasis, eczema, dermatitis, nodular eruption, palmoplantar pustulosis, squamous red lichen, amyloid lichen, ring granulomas, luster lichen, chronic discoid lupus erythematosus, fox 'oaid disease, thickening Include scarring, keloids, vulgaris, Schaumburg disease, and lymphoma.
- the external preparation for skin disease treatment of the present invention comprises at least an emulsion-type adhesive component, water, and a skin disease treatment drug as essential components, and is applied to the affected area while still containing water.
- a skin disease treatment drug as essential components
- a preparation called a conventional plaster is generally produced by drying an organic solvent solution of a fat-soluble polymer, but a suspension of the fat-soluble polymer in water is dried. (Emulsion method).
- the water permeability of the plaster agent is not sufficient. This is because even a plaster manufactured by the emulsion method is dried until it is substantially free of water, so the resulting fat-soluble polymer base has a complete affinity for water from the affected area. This is thought to be due to loss.
- the emulsion-type adhesive component used in the present invention is an adhesive component that can disperse the fine particles in water as a dispersion medium and maintain the state thereof, and is irritating to humans who are patients.
- the type is not particularly limited as long as it is low.
- preferable examples include poly (vinyl acetate), vinyl acetate acrylic acid ester copolymer, vinyl acetate vinyl ester copolymer such as vinyl acetate-versaic acid copolymer, butyl acetate copolymer, acetic acid Polyacetate burs such as vinyl-acrylic acid copolymer and vinyl acetate-acrylic acid amide copolymer; polyacrylic acid ester, acrylic acid ester, acrylic acid copolymer, acrylic acid ester-styrene copolymer, etc. Acid ester type;
- urethane-based materials include rubber latex systems such as natural rubber, polyisoprene, polybutadiene, and styrene-butadiene. From these, 1 can be selected, or a mixture of two or more of these can be used. Of these, polyacetate butyl is preferred.
- the "copolymerized product of ⁇ system and other monomers” refers to a copolymer having ⁇ as a main monomer (50% or more).
- ⁇ as a main monomer (50% or more).
- the copolymer is mainly used for improving water resistance and stability of emulsion.
- the blending amount of the emulsion type adhesive component is preferably 10% by mass or more and 75% by mass or less. If it is less than 10% by mass, it may be difficult to solidify, whereas if it exceeds 75% by mass, it may be difficult to disperse in water.
- the emulsion type adhesive component of the present invention contains water as an essential component.
- an adhesive component it is also possible to use an organic solvent solution of the adhesive component and form a film along with the evaporation of the organic solvent at the affected area.
- organic solvents are not safe and highly irritating, so they are not suitable as external preparation ingredients.
- water is safe and less irritating, so it is highly convenient as an external preparation ingredient.
- emulsion containing an adhesive component dispersed in water is administered to the affected area, the water in the affected area can be removed to some extent as the water in the preparation evaporates. Since it can be diffused, it is possible to suppress stuffiness and excessive skin permeation of drugs in the affected area.
- the blending amount of water in the external preparation according to the present invention is preferably 20% by mass or more and 85% by mass or less. If it is less than 20% by mass, it may be difficult to uniformly disperse the emulsion type adhesive component, and if the initial moisture content is not sufficient, there is a possibility that the moisture permeability of the formed film cannot be fully exhibited. is there. On the other hand, if it exceeds 85 mass%, it may take too long to solidify.
- the drug for treating skin diseases to be added to the external preparation of the present invention may be appropriately selected from those suitable for the treatment of the skin disease to be treated.
- Examples of the type include a steroid agent, a coal tar agent, a vitamin D3 derivative, a vitamin A derivative, salicylic acid, and an immunosuppressant, and one or more of these can be selected and used.
- a steroid agent a coal tar agent
- a vitamin D3 derivative a vitamin A derivative
- salicylic acid a derivative of a derivative
- an immunosuppressant an immunosuppressant
- the external preparation of the present invention may be mixed with a moisture transpiration promoter as necessary in order to adjust the solidification time, that is, the film formation time.
- a moisture transpiration accelerator ethanol and isopronool V can be exemplified.
- a surfactant may be added to improve the dispersion stability of the adhesive component.
- surfactants include polybulal alcohol, polysorbates, sucrose fatty acid esters, polyglycerin fatty acid esters and the like.
- a plasticizer may be blended as necessary.
- the plasticizer can adjust the physical performance of the formulation after film formation.
- plasticizers include esters such as isopropyl myristate and diisopropyl sebacate; macrogol; fatty acids; glycerin esters of fatty acids; alcohols and the like.
- excipients may be added.
- colorants may be added, fragrances, lubricants, binders, emulsifiers, thickeners, wetting agents, stabilizers, preservatives, solubilizers, buffering agents.
- a pH adjuster or the like may be added.
- the dosage form of the external preparation for skin disease treatment according to the present invention is not particularly limited as long as it is relatively plastic from the gist of the present invention.
- aerosols, ointments, creams, lotions Etc Even in the case of a dosage form such as an ointment, it is possible to reduce adhesion to clothes after the adhesive component is solidified.
- a general production method corresponding to the above-mentioned dosage form can be applied as it is. For example, add water, a drug for treating skin diseases, and other ingredients to the adhesive component emulsion and stir well until it is uniform.
- the external preparation for skin disease treatment of the present invention is applied to the affected area in consideration of the patient's symptoms and age, the appropriate dose of the skin disease treatment drug, and the like. At this time, as long as the preparation contains the amount of moisture specified in the present invention, it may be applied after being dried to some extent in advance.
- the external preparation of the present invention is not as quick-drying as the conventional cure agent, the adhesive component solidifies as the moisture evaporates, and therefore, the loss of the drug due to adhesion to clothes and the like can be reduced. In addition, compared to normal patches, administration along the unevenness of the skin is also possible at the bends and fingers.
- the external preparation of the present invention is extremely excellent as a means for treating skin diseases.
- betamethasone valerate and preservative are dissolved in decyl sebacate and macrogol, and 50% polyacetate bure-emulsion and purified water are added.
- a plaster was prepared using the solvent method with the formulation shown in Table 2. That is, butylhydroxytoluene, styrene-isoprene-styrene block copolymer, alicyclic saturated hydrocarbon resin, polybutene, liquid paraffin, decyl sebacate, and macrogol were added to toluene as a solvent and mixed uniformly. The mixture was applied to a plastic film with a uniform thickness (50 m) and dried at 80 ° C. for 20 minutes. Next, put a polyester cloth on the plaster surface Laminated together and cut to the desired size to produce a plaster.
- a nail polish was prepared with the formulation shown in Table 3.
- the film-forming cream preparation of Production Example 1 was adjusted to a film thickness after drying of 50 m, applied to a plastic film, and dried at 32 ° C for 30 minutes. Sample 1 was obtained by removing the formed film from the plastic film, and Sample 2 was obtained by removing the formed film by leaving it at room temperature for 7 days after drying. In addition, the following test was conducted using Sample 3 as the blaster agent of Comparative Production Example 1 and Sample 4 as the polysalt vinylidene film (trade name: Saran Wrap, manufactured by Asahi Kasei Co., Ltd.).
- Test Example 2 moisture permeability test
- the coating according to Production Example 1 can permeate moisture, but the coating with the nail polish does not show moisture permeability. This is thought to be because the solvent of the curing agent is only a highly volatile organic solvent and does not contain water, so that the formed film becomes very dense. Therefore, it is considered that if the skin disease affected area is covered with such a conventional film, the risk of infection is increased. Also, the solvent itself such as alcohol is not preferable because it has skin irritation.
- the film-forming cream preparation of Production Example 1 was applied to the center of the forearm of six subjects to form a film.
- the skin relative water content of the part was measured over time using a Corneometer (Courage + Khazaka Electronic BmbH, CM825PC). Measurements were taken before application and at 1, 3, and 6 hours after application.
- the same test subject treated the untreated case with the plaster agent or polyvinyl chloride film of Comparative Production Example 1 ( The measurement was performed in the same manner when the product name: Saran Wrap was attached. Figure the result
- the state of the affected area after treatment with the external preparation of the present invention was evaluated by the following index. a: Natural, almost the same as the skin other than the affected area.
- the amount of skin dropout during application of the external preparation of the present invention was evaluated by the following index. a: The skin peeled off from the coated surface.
- the external preparation of the present invention is remarkably effective as compared with conventional means for treating skin diseases, such as clearance of affected skin diseases and improvement of the quality of life of patients. .
- the external preparation for treatment of skin diseases of the present invention can actively dissipate the water in the affected area as the contained water evaporates, and can keep the water in the affected area moderate even after solidification.
- the disadvantages of the conventional hermetic closure therapy such as excessive skin absorption of the drug and stuffiness of the affected area.
- the affected area can be adhered and covered, so that the affected area can be protected and inconspicuous.
- diseases with excessive skin growth such as psoriasis, the skin residue can be adsorbed and removed together with the solidified preparation. Therefore, the external preparation for skin disease treatment of the present invention is extremely excellent in industry as it can provide an unprecedented means for treating skin diseases.
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004321974A JP2006131544A (ja) | 2004-11-05 | 2004-11-05 | 皮膚疾患治療用外用剤 |
JP2004-321974 | 2004-11-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006049078A1 true WO2006049078A1 (ja) | 2006-05-11 |
Family
ID=36319090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/019784 WO2006049078A1 (ja) | 2004-11-05 | 2005-10-27 | 皮膚疾患治療用外用剤 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP2006131544A (ja) |
WO (1) | WO2006049078A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023037983A1 (ja) * | 2021-09-09 | 2023-03-16 | 株式会社 資生堂 | 水溶性薬剤の皮膚浸透促進方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5381615A (en) * | 1976-12-03 | 1978-07-19 | Dai Ichi Seiyaku Co Ltd | Pasting drug base |
JPS54143517A (en) * | 1978-04-28 | 1979-11-08 | Hisamitsu Pharmaceut Co Inc | Novel poultice and its preparation |
JPS63159315A (ja) * | 1986-12-22 | 1988-07-02 | Yuutoku Yakuhin Kogyo Kk | パツプ剤 |
JP2004123633A (ja) * | 2002-10-03 | 2004-04-22 | Medorekkusu:Kk | 外用製剤 |
JP2004256396A (ja) * | 2003-02-24 | 2004-09-16 | Daikyo Yakuhin Kogyo Kk | 低皮膚刺激性硬膏剤 |
JP2004359585A (ja) * | 2003-06-03 | 2004-12-24 | Medorekkusu:Kk | 被膜形成型の副腎皮質ステロイド薬含有外用製剤 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS54140713A (en) * | 1978-04-24 | 1979-11-01 | Lion Dentifrice Co Ltd | Surgical antiiinflammatory and anodyne agent |
DE3612305A1 (de) * | 1986-04-11 | 1987-10-22 | Roehm Pharma Gmbh | Fluessige arzneiform zur therapie der psoriasis auf basis filmbildender polymere |
MXPA01010676A (es) * | 1999-04-23 | 2003-08-20 | Leo Pharm Prod Ltd | Composicion farmaceutica de vitamina d o un analogo de vitamina d y al menos un corticoesteroide. |
-
2004
- 2004-11-05 JP JP2004321974A patent/JP2006131544A/ja active Pending
-
2005
- 2005-10-27 WO PCT/JP2005/019784 patent/WO2006049078A1/ja active Application Filing
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5381615A (en) * | 1976-12-03 | 1978-07-19 | Dai Ichi Seiyaku Co Ltd | Pasting drug base |
JPS54143517A (en) * | 1978-04-28 | 1979-11-08 | Hisamitsu Pharmaceut Co Inc | Novel poultice and its preparation |
JPS63159315A (ja) * | 1986-12-22 | 1988-07-02 | Yuutoku Yakuhin Kogyo Kk | パツプ剤 |
JP2004123633A (ja) * | 2002-10-03 | 2004-04-22 | Medorekkusu:Kk | 外用製剤 |
JP2004256396A (ja) * | 2003-02-24 | 2004-09-16 | Daikyo Yakuhin Kogyo Kk | 低皮膚刺激性硬膏剤 |
JP2004359585A (ja) * | 2003-06-03 | 2004-12-24 | Medorekkusu:Kk | 被膜形成型の副腎皮質ステロイド薬含有外用製剤 |
Also Published As
Publication number | Publication date |
---|---|
JP2006131544A (ja) | 2006-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2098196C (en) | Method and systems for administering drugs transdermally using sorbitan esters as skin permeation enhancers | |
US4210633A (en) | Flurandrenolide film formulation | |
US8741333B2 (en) | Compositions and methods for treating dermatitis or psoriasis | |
JP5542665B2 (ja) | マトリックス型経皮投与剤およびその製造方法 | |
JP2003514835A (ja) | 瘢痕を治療する方法と組成物 | |
JP2005519126A (ja) | 活性成分の制御されたデリバリー用パッチ | |
JP2008501805A (ja) | 薬物の皮膚送達のための接着性外皮形成製剤とそれを使用する方法 | |
EP2370067B1 (en) | Antiviral patch | |
JP3159688B2 (ja) | 経皮吸収テープ剤 | |
JP2017154989A (ja) | S/o型貼付剤 | |
WO2000019986A1 (fr) | Bande pour absorption percutanee | |
JP7257410B2 (ja) | 含水系貼付剤 | |
JP4428903B2 (ja) | 非吸蔵性裏打ち層を有する吸蔵性経皮治療系 | |
WO2006049078A1 (ja) | 皮膚疾患治療用外用剤 | |
JPS635378B2 (ja) | ||
PT97505B (pt) | Processo para a preparacao de composicoes farmaceuticas para administracao transdermica, contendo 1-(4-etilfenil)-2-metil-3-(1-piperidinil)-1-propanona (eperisona) ou 2-metil-1-(4-metilfenil)-3-(1-piperidinil)-1-propanona (tolperisona) ou um dos seus sais, como ingrediente activo | |
JP3407073B2 (ja) | フィゾスチグミンの皮膚への投与のための経皮療法システム及びその製造方法 | |
JP3461401B2 (ja) | 経皮投与用テープ剤 | |
JP2004359585A (ja) | 被膜形成型の副腎皮質ステロイド薬含有外用製剤 | |
JP2887548B2 (ja) | 使用性の改善された含水性皮膚外用貼付剤 | |
JP3308628B2 (ja) | 医療用貼付剤 | |
JP3207257B2 (ja) | 貼付剤 | |
KR20030089908A (ko) | 천식치료제를 함유한 매트릭스형 패취 | |
JP7219177B2 (ja) | 非水系貼付剤 | |
WO2022188861A1 (zh) | 一种具有缓释功能的高分子水凝胶及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 05799351 Country of ref document: EP Kind code of ref document: A1 |